Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ADHD Drug Warnings In New Highlights Section Replaces Need For Black Box

Executive Summary

The ability to highlight warnings under FDA's new labeling rule may obviate the need for a "black box" warning against risks associated with attention deficit/hyperactivity disorder drugs, FDA's Pediatric Advisory Committee suggested March 22

You may also be interested in...



ADHD Drug MedGuides Show FDA’s Focus On Consumer Risk Communications

FDA's requirement that manufacturers of attention deficit/hyperactivity drugs develop patient medication guides illustrates the growing importance to the agency of communicating risks to the public

ADHD Drug MedGuides Show FDA’s Focus On Consumer Risk Communications

FDA's requirement that manufacturers of attention deficit/hyperactivity drugs develop patient medication guides illustrates the growing importance to the agency of communicating risks to the public

Shire Daytrana ADHD Patch To Launch In Early July With Some Class Labeling

Shire and manufacturing partner Noven expect an early July launch for Daytrana, the first transdermal patch for the treatment of attention deficit/hyperactivity disorder to receive FDA approval

Related Content

UsernamePublicRestriction

Register

PS047001

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel